{
    "clinical_study": {
        "@rank": "21911", 
        "brief_summary": {
            "textblock": "To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous\n      nystatin in patients with HIV infection who have completed protocol FDA 103C. To evaluate\n      the safety and potential antiviral activity of intravenous nystatin and oral didanosine\n      (ddI) administered in an alternating regimen in this patient population."
        }, 
        "brief_title": "A Study of Nystatin in HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients who have completed protocol FDA 103B are offered the option of receiving extended\n      maintenance. Patients who have received no prior ddI are treated either with intravenous\n      nystatin alone (at the same dose level administered in FDA 103B) or with a regimen of\n      intravenous nystatin and ddI alternating on 3-week cycles. Treatment continues for 12 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Completed 12 weeks of therapy with intravenous nystatin on protocol FDA 103B.\n\n          -  No evidence of toxicity or progression of disease on protocol FDA 103B. (See protocol\n             FDA 103B for initial entry requirements.)\n\n        Active drug or alcohol abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002313", 
            "org_study_id": "103C", 
            "secondary_id": "AR-91-35,606-005A"
        }, 
        "intervention": [
            {
                "intervention_name": "Nystatin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Didanosine", 
                "Nystatin"
            ]
        }, 
        "keyword": [
            "Nystatin", 
            "Didanosine", 
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77027"
                }, 
                "name": "Twelve Oaks Hosp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Extended Maintenance Protocol for Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection (NOTE: Continuation Study Intended Only for Patients Who Have Completed FDA 103B)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "citation": "Rios A, Brewton G, Crofoot G, Quesada J, Lenk R, Lopez-Berenstein G. A phase I-II clinical study of Nystatin-LF IV in patients with HIV infections. Int Conf AIDS. 1993 Jun 6-11;9(1):483 (abstract no PO-B26-2089)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002313"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Argus Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1994"
    }, 
    "geocoordinates": {
        "Twelve Oaks Hosp": "29.76 -95.369"
    }
}